Ollie Crowe (Fianna Fail) | Oireachtas source

Reference was made in the contribution to the capacity issues in countries where a TRIPS waiver could potentially be used. This has often been referenced by pharmaceutical companies since this debate began, and it has been repeatedly said that developing countries lack the capacity to manufacture vaccines. When I was doing research for this meeting, I came across an article by Stephanie Nolen in The New York Times, published on 22 October, which identified ten different locations in developing countries, including India, Thailand, South Africa and Indonesia. It was a detailed, well written piece. Ms Nolen had examined the key criteria, including existing facilities, human capital and so on. Did Mr. Moran or Mr. O'Connor see the piece and what is their reaction to it?